Is it "time to eliminate" time to elimination of symptoms as a primary trial endpoint for respiratory virus targeting drugs?
Where this comes from
- Record sourced from PubMed, PMID 41791419.
- Also identified by DOI 10.1093/infdis/jiag148 and PMC identifier 13148782.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Time to symptom elimination is a statistically inefficient endpoint for respiratory virus trials that ignores the most clinically relevant timepoints. Alternatively, clearance slope and area under the curve may efficiently capture improvement early during treatment when symptoms are most severe.